Aurora A conformational response to inhibitor binding
Biochemical assay · Fluorescently labeled human Aurora A protein, including unphosphorylated and phosphorylated states [1]
JNJ-7706621 weakly favored the DFG-in state in the inhibitor panel. This measures conformational response to binding rather than catalytic inhibition potency.
| Endpoint | Reported result | Reference |
|---|---|---|
| Direction and relative magnitude of Aurora A conformational change | Qualitative response Weakest DFG-in inducer among the 14 DFG-in-inducing compounds profiled | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 nM to 5 μM inhibitor titration; 50 nM FRET sensor
- Method
- Cell-free TR-FRET in 384-well plates
- Vehicle
- DMSO baseline shown in Fig. 3B; final solvent percentage not established from retrieved main text
- Reported limits
- Incubation duration and compound vendor/lot details were not established from the retrieved main text. SI was not retrieved. No IC50 or exact distance was extracted.
Methods and source locations
Compound reported in the paper: JNJ-7706621
Evidence for the named compound in the reported assay; no salt conversion or validation of the catalog lot.
Fig. 3A–D and caption; Results: Type I Inhibitors Stabilize the DFG-In State by Promoting Active Site Closure; Materials and Methods: FRET sensor, TR-FRET assay and data fitting
Direction and relative magnitude of Aurora A conformational change: Time-resolved FRET; activation-loop distance fitting; apo/DMSO baseline; donor-only and donor-plus-acceptor controls. Fig. 3A reports fitted values with 95% confidence intervals. — Fig. 3A–D and caption; Results: Type I Inhibitors Stabilize the DFG-In State by Promoting Active Site Closure; Materials and Methods: FRET sensor, TR-FRET assay and data fitting